** KBC maintained its buy rating for Argenx ARGX.BR after
the Dutch biopharmaceutical company complemented its Q3 results
with regulatory and commercial announcements
** 9-month revenues and operating income were up, with FY
cash burn guidance confirmed (nGNE4q8rwf)
** The efgar drug is nearing US FDA approval in December,
with additional approvals expected next year in Japan and the EU
(nGNX8yk3nH)
** The broker labels co's efgar drug as "one of the biggest
drug launches of the year"
** Discussions are in place, through partner Zai Lab, to
explore efgar drug approval in China
** Co also announced a partnership with Medison for
regulatory filing and commercialisation in Israel
** "2022 strikes us as an eventful year for Argenx," the
broker adds, calling co a growing biotech "trailblazer" in
Europe
**Out of 13 analysts that cover the stock, ten rate it
"strong buy" or "buy, and three rate it "hold"
(Reporting by Olivier Sorgho in Gdansk)
((olivier.sorgho@tr.com))